Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FR236913 is an experimental small molecule compound belonging to the class of organic compounds known as n-alkylindoles. It has been identified as an inhibitor of adenosine deaminase, a key enzyme involved in purine metabolism and adenosine homeostasis. The compound's chemical formula is C24H26N6O3 and it has a molecular weight of approximately 446.5 g/mol. While its primary mechanism is inhibition of adenosine deaminase, there are no approved indications or associated clinical trials reported for this agent to date[1][2][3][4]. It has been studied in silico for potential activity against viral proteases, including SARS-CoV-2 main protease[7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on FR236913.